Dark

KALA
Kala Pharmaceuticals Inc
stock NASDAQ

At Close

3/27/2023 3:59:38 PM EDT

15.03USD-3.468%(-0.54)1,012,471

12.02Bid 15.13Ask 3.11Spread IEX

Pre-market

3/27/2023 9:21:30 AM EDT

16.22USD+4.175%(+0.65)0

After-hours

1969-12-31

0.00USD0.000%(0.00)0

Overview Option Chain HistoricalMore

open chart

Market Cap

30.443M

CEO

Mark Iwicki

Headquarters

Watertown, Massachusetts, USA

Industry

Drug Manufacturers-Specialty & Generic

Next Earnings

2023-05-08 (41d)

Last Split

2022-10-211for50reverse

OMER XLV

KALA Stats

Avg. Vol. 10 Day

349,308

Avg. Vol. 30 Day

1,551,346

Employees

Market Cap

30,443,190

Shares Out.

2,025,495

Float

1,576,260

On/Off Exchange

55%/45%

6 Month Beta

0.75

1 Year Beta

0.93

2 Year Beta

0.92

3 Year Beta

0.83

52 Week Low

3.54

52 Week High

93.50

SMA50

14.64

SMA200

12.76

1 Week

-0.79%

1 Month

+48.37%

3 Month

+20.43%

6 Month

+30.70%

1 Year

-82.82%

2 Year

-95.18%

5 Year

-98.16%

Dec 17, 2021

04:01PM EST Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). GlobeNewswire Inc

Nov 24, 2021

03:03PM EST Kala Pharma 13D Filing From Mark Blumenkranz Shows Activist Stake On 7.4% In Co. Benzinga

Nov 18, 2021

04:01PM EST Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). GlobeNewswire Inc

Nov 15, 2021

11:11AM EST Kala Sees Submitting Investigational New Drug Application To FDA For KPI-012; Subject To Regulatory Clearance, Sees Initiating Phase 2/3 Trial For Persistent Corneal Epithelial Defect In Q3'22 Benzinga

11:10AM EST Kala Pharmaceuticals Q3 EPS $(0.43), Inline, Sales $3.10M Miss $5.16M Estimate Benzinga

More News

Profile

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

KALA Stock Summary

Kala Pharmaceuticals Inc (NASDAQ:KALA) stock price today is $15.03, and today's volume is 1,012,471. KALA is down -3.468% today. The 30 day average volume is 1,551,346. KALA market cap is 30.443M with 2,025,495 shares outstanding.